In 2020, MB also initiated the process of joining an ENGOT/CEEGOG phase II/III industry-sponsored trial (navtemadlin maintenance therapy for TP53-wild-type advanced or recurrent endometrial cancer). The gene discussed is TP53; the disease is endometrial cancer.